Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRFX
stocks logo

PRFX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for PainReform Ltd (PRFX.O) is -0.02, compared to its 5-year average forward P/E of -3.17. For a more detailed relative valuation and DCF analysis to assess PainReform Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.17
Current PE
-0.02
Overvalued PE
0.72
Undervalued PE
-7.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PRFX News & Events

Events Timeline

(ET)
2025-12-02
09:30:00
PainReform Initiates Development of OcuRing-K to Enhance Ocular Therapy
select
2025-11-12 (ET)
2025-11-12
09:08:09
PainReform's DeepSolar Progresses in Creating AI-Powered Reporting System
select
2025-10-01 (ET)
2025-10-01
09:32:49
PainReform Reports First Half EPS of $1.09 Compared to ($63.15) Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-02Newsfilter
PainReform Initiates OcuRing-K Development Plan Targeting 4.5 Million Cataract Surgeries Annually
  • Development Plan Launch: PainReform has officially initiated the development plan for OcuRing-K following its majority investment in LayerBio, aiming to provide sustained-release ocular therapy for approximately 4.5 million cataract surgeries performed annually, significantly enhancing postoperative recovery experiences for patients.
  • Clinical Trial Progress: The development of OcuRing-K has advanced to Phase II clinical trials, expected to reduce postoperative pain and inflammation while decreasing patient reliance on traditional eye drops, thereby improving patient compliance and treatment outcomes.
  • Significant Market Potential: With a global cataract surgery market exceeding $9 billion annually, OcuRing-K's innovative design aims to simplify postoperative management and reduce medication burdens for patients, positioning it to capture a significant share in a high-demand market.
  • Clear Technological Advantage: OcuRing-K's sustained-release mechanism provides stable drug concentrations while minimizing systemic side effects, particularly beneficial for elderly patients, marking PainReform's strategic positioning and technological innovation in the ophthalmic treatment sector.
[object Object]
Preview
3.5
12-02Globenewswire
PainReform Initiates OcuRing-K Development Plan Targeting Ophthalmic Market
  • Development Plan Launch: PainReform officially initiates the development plan for OcuRing-K following its majority investment in LayerBio, aiming to provide a drop-less sustained-release therapy to improve pain management after cataract surgery, which is expected to significantly enhance patient treatment experiences.
  • Clinical Trial Progress: OcuRing-K is advancing towards Phase II clinical trials, designed to reduce postoperative pain and inflammation through lower drug exposure, which is anticipated to offer more stable efficacy, particularly for elderly patient populations.
  • Significant Market Potential: With approximately 4.5 million cataract surgeries performed annually in the U.S. and a global surgical market exceeding $9 billion, the introduction of OcuRing-K is poised to capture a substantial share in this high-demand market, enhancing PainReform's competitive position.
  • Clear Technological Advantages: OcuRing-K's sustained-release mechanism allows for direct drug delivery to ocular target tissues, eliminating the need for multiple applications of traditional eye drops and reducing contamination risks, which is expected to improve patient compliance and minimize side effects.
[object Object]
Preview
3.5
11-12Newsfilter
PainReform's DeepSolar Progresses in Developing AI-Powered Automated Reporting System for Solar Asset Evaluation

  • Automated Reporting Engine Development: PainReform's DeepSolar unit is advancing an AI-powered automated reporting engine to enhance solar asset performance analysis, reducing manual data aggregation and producing customized reports quickly.

  • Importance of Performance Reports: The new reporting system aims to provide essential insights for executive management, investors, and asset owners, helping them assess operational performance, identify issues, and evaluate ROI efficiently.

  • AI Integration and Customization: The platform will consolidate data from various sources and allow users to customize the depth of analysis, visualization style, and reporting frequency, all integrated within DeepSolar's AI analytics framework.

  • Company Overview: PainReform Ltd. focuses on reformulating therapeutics and developing AI-driven energy optimization technologies, reflecting its commitment to innovation in healthcare and sustainable energy sectors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PainReform Ltd (PRFX) stock price today?

The current price of PRFX is 1.02 USD — it has increased 8.51 % in the last trading day.

arrow icon

What is PainReform Ltd (PRFX)'s business?

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

arrow icon

What is the price predicton of PRFX Stock?

Wall Street analysts forecast PRFX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRFX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PainReform Ltd (PRFX)'s revenue for the last quarter?

PainReform Ltd revenue for the last quarter amounts to -7.35M USD, increased 226.15 % YoY.

arrow icon

What is PainReform Ltd (PRFX)'s earnings per share (EPS) for the last quarter?

PainReform Ltd. EPS for the last quarter amounts to -4954000.00 USD, increased 147.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for PainReform Ltd (PRFX)'s fundamentals?

The market is revising No Change the revenue expectations for PainReform Ltd. (PRFX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -28.17%.
arrow icon

How many employees does PainReform Ltd (PRFX). have?

PainReform Ltd (PRFX) has 2 emplpoyees as of December 05 2025.

arrow icon

What is PainReform Ltd (PRFX) market cap?

Today PRFX has the market capitalization of 4.11M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free